Last updated on February 2018

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC A/B.

Detailed Study Description

Transarterial chemoembolization (TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of TACE for patients with large hepatocellular carcinoma staged BCLC A/B especially for those with tumor larger than 10 cm. Our previous prospective study also revealed similar results of large HCC patients treated with TACE. Recently, the results of our preliminary pilot study suggested that, compared with TACE, hepatic arterial infusion chemotherapy (HAIC) may improve the survivals for HCC with large HCC. Thus, the investigators carried out this prospective randomized control to demonstrate the superiority of HAIC over TACE.

Clinical Study Identifier: NCT02973685

Contact Investigators or Research Sites near you

Start Over

Wusheng Yu, MD

Dongguan People's Hospital
Dongguan, China
  Connect »

Ming Shi, MD

Cancer Center Sun Yat-sen University
Guangzhou, China
  Connect »

Guosheng Tan, MD

The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
  Connect »

Jinghua Chen, MD

Guangzhou Twelfth People's Hospital
Guangzhou, China
  Connect »

Shijie Zhang, MD

Kaiping Central Hospital
Kaiping, China
  Connect »

Xiaoping Wu, MD

The First Affiliated Hospital of University Of South China
Hengyang, China
  Connect »

Xin Zheng, MD

The First Affiliated Hospital Of Xi'an Jiaotong University
Xi'an, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.